Looking to publish in Clinical Cancer Research? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowClinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative imaging, and clinical genetics.
Looking to publish in Clinical Cancer Research? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Clinical Cancer Research accepts the following article types. Click on an article type to view submission instructions.
Original Research Articles
Review Manuscript
Meta-Analysis
Systematic Reviews
Clinical Trials
Recent Publications
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Attaya Suvannasankha, Mengying Li, Omonefe Omofuma, Christian Hampp, Matthew Phelan, Alexander Breskin, Ping Shao, Tito Roccia, Nandita Mukherjee, Anju Shrestha, Daniel Lee, Jacob Glass, Glenn S. Kroog, Karen Rodriguez Lorenc
The biology of hypomorphic TP53 variants and implications for clinical management
Renyta Moses, Jacquelyn Powers, Alison S. Levine, Judy E. Garber, Suzanne P. MacFarland, Huma Q. Rana, Maureen E. Murphy, Kara N. Maxwell
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses
Lea Ruge, Felix John, Malte Verheyen, Richard Riedel, Sebastian Michels, Lucia Nogova, Heather Scharpenseel, Rieke Fischer, Sofia Stilianakis, Janna Siemanowski-Hrach, Jana Fassunke, Anna Rasokat, Anna Kron, Marvin Kirsch, Monika Serke, Jutta Kappes, Kato Kambartel, Udo Siebolts, Sabine Merkelbach-Bruse, Reinhard Büttner, Jürgen Wolf, Matthias Scheffler
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial
Cheng Xu, Si-Yang Wang, Man Nie, Kun-Yu Yang, Xin-Qiong Huang, Song Qu, Hui Chen, Liang-Fang Shen, Jing Huang, Fan Zhang, Ying-Peng Peng, Liang-Liang Shi, Xiao-Hua Hong, Zhan-Jie Zhang, Ling-Long Tang, Ling Guo, Pu-Yun Ouyang, Jian-Ming Gao, Yan-Ping Mao, Ying Huang, Rui Guo, Li-Zhi Liu, Li Tian, Hao-Jiang Li, Ji-bin Li, Jun Ma, Yi Xia, Qing-Qing Cai
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma
Hui K. Gan, Lawrence Cher, Po-ling Inglis, Zarnie Lwin, Ashray Gunjur, Adi Balasubramanian, Andrew Schmidt, Christian W. Wichmann, Nancy Guo, Sze Ting Lee, Paul Thomas, Fiona E. Scott, Chloe Shard, Kate Fluck, Nicole Coombs, Jodie Palmer, Mary E. Vail, Stacey Allen, Ashwini Patil, Bhupinder Pal, Graeme J. O'Keefe, Sylvia J. Gong, Gaia Ninatti, Bryan W. Day, Guillermo A. Gomez, Peter W. Janes, Andrew M. Scott
Frequently asked questions
How long does it take to publish?
AACR member authors may receive a full refund of the journal publication fee if the time from completion of submission to the first decision after external peer review exceeds 60 days.
Reformat to Clinical Cancer Research using Livewrite PremiumIs a cover letter required?
Authors are strongly encouraged to upload a cover letter for initial submission.
Reformat to Clinical Cancer Research using Livewrite PremiumWhat are the publication costs?
Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.
Reformat to Clinical Cancer Research using Livewrite Premium